Loading...
Market
To how many countries will the Shield Test expand following FDA approval by the end of 2025?
5
Resolution / Starting Odds
No expansion • 25%
Expansion to 1-3 countries • 25%
Expansion to 4-6 countries • 25%
Expansion to more than 6 countries • 25%
Guardant Health’s official announcements or major healthcare news
Story
FDA Panel Recommends Approval of Guardant Health's Shield Blood Test, Stock Jumps 18.6%
May 23, 2024, 10:20 PM
An independent panel of advisers to the U.S. Food and Drug Administration (FDA) has recommended the approval of Guardant Health's blood-based test for detecting colorectal cancer. The test, known as the Shield test, is designed to screen for colon and rectal cancers and has been endorsed by the FDA advisory panel as a non-invasive screening option. The panel voted by large majorities that the test is safe and effective, and that its benefits outweighed its risks. If approved, it will be the first blood screening test for colorectal cancer that meets the requirements for Medicare reimbursement. The panel's recommendation marks a significant step towards FDA approval, although colonoscopies remain the gold standard for diagnosing colon cancers. Guardant Health's stock saw a significant increase of 18.6% in pre-market trading following the panel's endorsement.
View original story
Similar markets
Available in Europe • 25%
Available in Asia • 25%
Available in South America • 25%
Not available outside the US • 25%
0 countries • 20%
1-3 countries • 20%
4-6 countries • 20%
7-9 countries • 20%
10 or more countries • 20%
1-5 countries • 33%
6-10 countries • 33%
More than 10 countries • 34%
No expansion • 25%
1-3 countries • 25%
4-6 countries • 25%
More than 6 countries • 25%
< 10% adoption • 33%
10% to 30% adoption • 33%
> 30% adoption • 33%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
16 or more countries • 25%
None • 25%
1-3 • 25%
4-6 • 25%
More than 6 • 25%
Available in over 20 countries • 33%
Available in 10-20 countries • 33%
Available in less than 10 countries • 33%
Yes • 50%
No • 50%
0-5 countries • 25%
6-10 countries • 25%
11-20 countries • 25%
More than 20 countries • 25%
Less than 10 • 25%
10-20 • 25%
21-50 • 25%
More than 50 • 25%